{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T08:16:14Z","timestamp":1648714574098},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00059-017-4650-6","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T13:35:04Z","timestamp":1513085704000},"page":"379-389","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patienten mit einer tragbaren Defibrillatorweste (\u201ewearable cardioverter-defibrillator\u201c, WCD)"],"prefix":"10.1007","volume":"44","author":[{"given":"A.","family":"Schlitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Noutsias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. H.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. U.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"4650_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cpcardiol.2015.01.002","volume":"40","author":"VP Kuriachan","year":"2015","unstructured":"Kuriachan VP, Summer GL, Mitchell LB (2015) Sudden cardiac death. Curr Probl Cardiol 40:133\u2013200","journal-title":"Curr Probl Cardiol"},{"key":"4650_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMicm1612408","volume":"377","author":"L Chen","year":"2017","unstructured":"Chen L, Jhund PS, Petrie MC et\u00a0al (2017) Declining risk of sudden death in heart failure. N\u00a0Engl J Med 377:41\u201351","journal-title":"N Engl J Med"},{"key":"4650_CR3","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/j.ijcard.2007.04.178","volume":"128","author":"M Noutsias","year":"2008","unstructured":"Noutsias M, Pauschinger M, Gross U, Lassner D, Schultheiss HP, Kuhl U (2008) Giant-cell myocarditis in a\u00a0patient presenting with dilated cardiomyopathy and ventricular tachycardias treated by immunosuppression: a\u00a0case report. Int J Cardiol 128:e58\u20139","journal-title":"Int J Cardiol"},{"key":"4650_CR4","first-page":"323","volume-title":"Algorithms in heart failure","author":"M Noutsias","year":"2016","unstructured":"Noutsias M (2016) Myocarditis. In: Maisel AS, Filippatos G (Hrsg) Algorithms in heart failure, Bd. 1. Jaypee Brothers Medical Publishers, New Delhi, S\u00a0323\u2013345"},{"key":"4650_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-017-9641-4","author":"JG Westphal","year":"2017","unstructured":"Westphal JG, Rigopoulos AG, Bakogiannis C et\u00a0al (2017) The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Fail Rev. \n                    https:\/\/doi.org\/10.1007\/s10741-017-9641-4","journal-title":"Heart Fail Rev"},{"key":"4650_CR6","first-page":"1601","volume":"17","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 17:1601\u20131687","journal-title":"Europace"},{"key":"4650_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"key":"4650_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/CIRCEP.114.001623","volume":"7","author":"AC Ruwald","year":"2014","unstructured":"Ruwald AC, Schuger C, Moss AJ et al (2014) Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol 7:785\u2013792","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4650_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00392-017-1090-5","volume":"106","author":"D Duncker","year":"2017","unstructured":"Duncker D, Westenfeld R, Konrad T et al (2017) Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a\u00a0German multi-centre analysis. Clin Res Cardiol 106:582\u2013589","journal-title":"Clin Res Cardiol"},{"key":"4650_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12181-015-0651-y","volume":"9","author":"JO Schwab","year":"2015","unstructured":"Schwab JO, B\u00e4nsch D, Israel C, Novak B (2015) Stellungnahme zum Einsatz des tragbaren Cardioverter\/Defibrillators. Kardiologe 9:165\u2013170","journal-title":"Kardiologe"},{"key":"4650_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1474515111435885","volume":"12","author":"IM Morken","year":"2013","unstructured":"Morken IM, Norekval TM, Isaksen K et\u00a0al (2013) Increased confidence to engage in physical exertion: older ICD recipients\u2019 experiences of participating in an exercise training programme. Eur J Cardiovasc Nurs 12:261\u2013268","journal-title":"Eur J Cardiovasc Nurs"},{"key":"4650_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2013.11.045","volume":"171","author":"H Ismail","year":"2014","unstructured":"Ismail H, McFarlane JR, Dieberg G, Smart NA (2014) Exercise training program characteristics and magnitude of change in functional capacity of heart failure patients. Int J Cardiol 171:62\u201365","journal-title":"Int J Cardiol"},{"key":"4650_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jacc.2010.04.016","volume":"56","author":"MK Chung","year":"2010","unstructured":"Chung MK, Szymkiewicz SJ, Shao M et al (2010) Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J\u00a0Am Coll Cardiol 56:194\u2013203","journal-title":"J Am Coll Cardiol"},{"key":"4650_CR14","first-page":"229","volume":"128","author":"T Odeneg","year":"2016","unstructured":"Odeneg T, Ebner C, Mortl D et\u00a0al (2016) Indications for and outcome in patients with the Wearable Cardioverter Defibrillator (WCD)\u2014results of the Austrian WCD registry. Wien Klin Wochenschr 128:229","journal-title":"Wien Klin Wochenschr"},{"key":"4650_CR15","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.amjcard.2011.07.021","volume":"108","author":"M Rao","year":"2011","unstructured":"Rao M, Goldenberg I, Moss AJ et\u00a0al (2011) Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol 108:1632\u20131638","journal-title":"Am J Cardiol"},{"key":"4650_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.110.940619","volume":"122","author":"AC Pouleur","year":"2010","unstructured":"Pouleur AC, Barkoudah E, Uno H et\u00a0al (2010) Pathogenesis of sudden unexpected death in a\u00a0clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation 122:597\u2013602","journal-title":"Circulation"},{"key":"4650_CR17","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa041489","volume":"351","author":"SH Hohnloser","year":"2004","unstructured":"Hohnloser SH, Kuck KH, Dorian P et al (2004) Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N\u00a0Engl J Med 351:2481\u20132488","journal-title":"N Engl J Med"},{"key":"4650_CR18","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.jacc.2013.05.086","volume":"62","author":"AE Epstein","year":"2013","unstructured":"Epstein AE, Abraham WT, Bianco NR et al (2013) Wearable cardioverter-defibrillator use in patients perceived to be at high risk early postmyocardial infarction. J\u00a0Am Coll Cardiol 62:2000\u20132007","journal-title":"J Am Coll Cardiol"},{"key":"4650_CR19","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/eurheartj\/eht167","volume":"34","author":"HU Klein","year":"2013","unstructured":"Klein HU, Goldenberg I, Moss AJ (2013) Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J 34:2230\u20132242","journal-title":"Eur. Heart J."},{"key":"4650_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/europace\/euw180","volume":"19","author":"S Reek","year":"2016","unstructured":"Reek S, Burri H, Roberts PR, Perings Ch, Epstein AE, Klein HU (2016) The wearable cardioverter-defibrillator. Current technology and evolving indications. Europace 19:335\u2013345","journal-title":"Europace"},{"key":"4650_CR21","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.115.015677","volume":"132","author":"V Kutyifa","year":"2015","unstructured":"Kutyifa V, Moss AJ, Klein H et al (2015) Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the prospective registry of patients using the Wearable Cardioverter Defibrillator (WEARIT-II registry). Circulation 132:1613\u20131619","journal-title":"Circulation"},{"key":"4650_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.115.019124","volume":"134","author":"NK W\u00e4\u00dfnig","year":"2016","unstructured":"W\u00e4\u00dfnig NK, Gunther M, Quick S et al (2016) Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 134:635\u2013643","journal-title":"Circulation"},{"key":"4650_CR23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.hrthm.2015.03.061","volume":"12","author":"CA Healy","year":"2015","unstructured":"Healy CA, Carillo RG (2015) Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal. A cost-effective evaluation. Heart Rhythm 12:1565\u20131573","journal-title":"Heart Rhythm"},{"key":"4650_CR24","first-page":"1929","volume":"6","author":"GD Sanders","year":"2015","unstructured":"Sanders GD, Owens DK, Hlatky MA (2015) Potential cost-effectiveness of wearable cardioverter-defibrillator early after myocardial infarction. J\u00a0Innov Card Rhythm Manag 6:1929\u20131940","journal-title":"J Innov Card Rhythm Manag"},{"key":"4650_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/1741826711430926","volume":"19","author":"L Vanhees","year":"2012","unstructured":"Vanhees L, Geladas N, Hansen D et\u00a0al (2012) Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 19:1005\u20131033","journal-title":"Eur J Prev Cardiol"},{"key":"4650_CR26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jacc.2012.06.036","volume":"60","author":"R Belardinelli","year":"2012","unstructured":"Belardinelli R, Georgiou D, Cianci G, Purcaro A (2012) 10-year exercise training in chronic heart failure: a\u00a0randomized controlled trial. J\u00a0Am Coll Cardiol 60:1521\u20131528","journal-title":"J Am Coll Cardiol"},{"key":"4650_CR27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.112.123117","volume":"126","author":"O Rognmo","year":"2012","unstructured":"Rognmo O, Moholdt T, Bakken H et al (2012) Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 126:1436\u20131440","journal-title":"Circulation"},{"key":"4650_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjhf\/hfs015","volume":"14","author":"I Kindermann","year":"2012","unstructured":"Kindermann I, Fischer D, Karbach J et al (2012) Cognitive function in patients with decompensated heart failure: the Cognitive Impairment in Heart Failure (CogImpair-HF) study. Eur J Heart Fail 14:404\u2013413","journal-title":"Eur J Heart Fail"},{"key":"4650_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s001150101168","volume":"73","author":"B Hesslinger","year":"2002","unstructured":"Hesslinger B, H\u00e4rter M, Barth J et al (2002) Comorbidity of depressive disorders and cardiovascular diseases. Implications for diagnosis, pharmaco- and psychotherapy. Nervenarzt 73:205\u2013217","journal-title":"Nervenarzt"},{"key":"4650_CR30","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/eurheartj\/eht270","volume":"34","author":"EE Steinke","year":"2013","unstructured":"Steinke EE, Jaarsma T, Barnason SA et\u00a0al (2013) Sexual counselling for individuals with cardiovascular disease and their partners: a\u00a0consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). Eur Heart\u00a0J 34:3217\u20133235","journal-title":"Eur Heart J"},{"key":"4650_CR31","series-title":"Berichte der Bundesanstalt f\u00fcr Stra\u00dfenwesen, Mensch und Sicherheit Heft M 115","volume-title":"Begutachtungsleitlinien zur Kraftfahreignung, Stand: 28. Dezember 2016","author":"Bundesanstalt f\u00fcr Stra\u00dfenwesen, Mensch und Sicherheit","year":"2016","unstructured":"Bundesanstalt f\u00fcr Stra\u00dfenwesen, Mensch und Sicherheit (2016) Begutachtungsleitlinien zur Kraftfahreignung, Stand: 28. Dezember 2016. Berichte der Bundesanstalt f\u00fcr Stra\u00dfenwesen, Mensch und Sicherheit Heft M 115. (\n                    www.bast.de\/DE\/Verkehrssicherheit\/Fachthemen\/BLL\/BLL-Download.html\n                    \n                  )"},{"key":"4650_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00059-006-2870-2","volume":"31","author":"B Bjarnason-Wehrens","year":"2016","unstructured":"Bjarnason-Wehrens B, Held K, Karoff M (2016) Heart groups in Germany-current situation and prospects. Herz 31:559\u2013565","journal-title":"Herz"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4650-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:16:10Z","timestamp":1566836170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4650-6"}},"subtitle":["Verschreibung, Wirkweise und Nachsorge"],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4650"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4650-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]},"assertion":[{"value":"4 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A. Schlitt hat Beraterhonorare von Boehringer Ingelheim, Astra Zeneca und Sanofi-Aventis sowie Vortragshonorare und Entsch\u00e4digungen f\u00fcr Konferenzauslagen und Reisekosten von ZOLL, Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Novartis, Servier, Boehringer Ingelheim, Merck Sharp & Dohme und Bayer erhalten. Er hat finanzielle Unterst\u00fctzung (Drittmittel) f\u00fcr Studien von GlaxoSmithKline, Sanofi-Aventis, Mitsubishi, Endotis, Bayer, Boehringer Ingelheim, Novartis, Actelion und Bristol-Myers Squibb erhalten. \n\t\t\t\t\t\tM.\u00a0Guha hat Vortragshonorare von Bayer Vital, Bristol-Myers Squibb, Berlin-Chemie, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis und ZOLL sowie Honorare f\u00fcr Beratert\u00e4tigkeiten von Novartis, Bristol-Myers Squibb, Pfizer und Sanofi-Aventis erhalten. Au\u00dferdem war er an klinischen Studien von Merck Sharp & Dohme, Sanofi-Aventis und Novartis beteiligt. \n\t\t\t\t\t\tM.\u00a0Noutsias hat finanzielle Unterst\u00fctzung von der Deutschen Forschungsgemeinschaft (DFG) im Rahmen des Sonderforschungsbereichs (SFB) TR19 (Transregio\u00a019 \u201eInflammatory Cardiomyopathy\u201c [TP B2]) sowie des Foundation Grant \u201eT\u00a0cell Functionality\u201c der Universit\u00e4tsklinik Giessen und Marburg (UKGM 10\/2009) erhalten. Er war im Zeitraum von Juni 2004 bis Juni 2008 Berater des Instituts Kardinale Diagnostik und Therapie (IKDT), Berlin, und hat Vortragshonorare erhalten und\/oder war Mitglied in Advisory Boards von AstraZeneca, Bayer, Fresenius, Miltenyi Biotech, Novartis, Pfizer and ZOLL.\n\t\t\t\t\t\tH.U.\u00a0Klein hat Forschungsunterst\u00fctzung, Vortragshonorare sowie Entsch\u00e4digungen f\u00fcr Konferenzauslagen und Reisekosten von ZOLL Medical Corp. Pittsburgh, PA, USA, und ZOLL-CMS Deutschland erhalten.\n\t\t\t\t\t\tH.H.\u00a0Klein gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}